• Article  

      Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes 

      Pentheroudakis, George; Kotoula, V.; Roock, W. De; Kouvatseas, G.; Papakostas, P.; Makatsoris, T.; Papamichael, D.; Xanthakis, I.; Sgouros, J.; Televantou, D.; Kafiri, G.; Tsamandas, A. C.; Razi, E. D.; Galani, E.; Bafaloukos, Dimitrios; Efstratiou, I.; Bompolaki, I.; Pectasides, Dimitrios; Pavlidis, Nicholas; Tejpar, S.; Fountzilas, George (2013)
      Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order ...
    • Article  

      KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: A cohort study 

      Negru, S.; Papadopoulou, E.; Apessos, A.; Stanculeanu, D. L.; Ciuleanu, E.; Volovat, C.; Croitoru, A.; Kakolyris, S.; Aravantinos, Gerasimos; Ziras, N.; Athanasiadis, E.; Touroutoglou, N.; Pavlidis, Nicholas; Kalofonos, H. P.; Nasioulas, G. (2014)
      Objectives: Treatment decision-making in colorectal cancer is often guided by tumour tissue molecular analysis. The aim of this study was the development and validation of a high-resolution melting (HRM) method for the ...